User    ㄩ
   Passwordㄩ
             
 Registerㄐ       
 Forgot Passwordˋ
 
 Your locationㄩHome - News - News - Industry News
 
Stem cell technologies-changes to US regulations
 
Release Dateㄩ2009.06.10 News sourcesㄩBeijing Xianglong Huanyu Biotechnology Co., Ltd Viewsㄩ
 

Stem cell technologies 每 changes to US regulations to give exciting new hopes and potentially vast commercial opportunities 每 brand new indepth study
Stem cells represent one of the most promising medical breakthroughs of all time, as our new market report explains. Currently, in 2009, the new US administration is lifting some major restrictions on stem cells technologies. This developmental obstacle now removed, all types of stem cells are available for expanding the therapeutic and commercial potentials, as our new report Stem Cells 每 The Hype & Hope 每 World Analysis 2009-2024 explains. Based upon the cells that create and renew all tissues potentially, stem cell therapies could revolutionise the treatment of disease, especially through tissue and organ replacement. Stem cells could provide revolutionary treatments for conditions from diabetes to multiple sclerosis, and from myocardial infarction to chronic obstructive pulmonary disease, amongst many others. Stem cell lines could also change the way pharmaceutical companies assess new chemical entities during R&D.


A conservative estimate places the potential market  of stem cells at over $150bn by late next decade. But will stem cell products be ready to meet regulatory hurdles and market requirements? Where is stem cell research heading today? What stem cell therapies are likely to hit the market from 2009 onwards? Where does the highest ㄕ#118alue lie in the short-term? What are the commercial threats there? This new visiongain report answers these and other crucial questions about this important developing field, one with vast commercial potential.


Comprehensive analysis of the global stem cells sector and market
Stem Cells 每 The Hype & Hope 每 World Analysis 2009-2024 examines stem cells technology critically. We used a comprehensive review of information sources, including consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of important contemporary issues, especially relevant commercial drivers and restraints. This report also covers regulations and ethics. Sources used include commercial databases, industry news, published reports, policy documents and economic research. Importantly, visiongain applied rigorous financial forecasting, qualitative analyses and the assessment of unmet needs. The result is a comprehensive market- and industry-centred report with detailed analysis and informed opinion that you will not find elsewhere.

 

 
 
Home |  About us |  Products |  News |  Recruitment |  Download |  MemberCenter |  Shopping Cart |  Service |  BBS |  Contact us | 
Copyright 2009 Beijing Xianglong Huanyu Biotechnology Co., Ltd